Wolfgang Willenbacher

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

David H. Henry, Luís Costa, François Goldwasser et al. · Journal of Clinical Oncology · 2011 · 1.3K citations · Full text

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology · 2018 · 427 citations

Bone Disease, Hematological Malignancy, Bone Health +10

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Peter Borchmann, Helen Goergen, Carsten Kobe et al. · The Lancet · 2017 · 372 citations

Positron Emission Tomography, Advanced-stage Hodgkin, Lymphoid Neoplasia +9

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

Radhakrishnan Ramchandren, Eva Domingo‐Doménech, Antonio Rueda et al. · Journal of Clinical Oncology · 2019 · 250 citations · Full text

Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats

Igor Theurl, Andrea Schroll, Thomas Sonnweber et al. · Blood · 2011 · 187 citations · Full text